Synonyms: EVP 6124 | EVP-6124 | EVP6124
Compound class:
Synthetic organic
Comment: This compound was developed as part of EnVivo Pharmaceuticals alpha-7 agonist program [3]. The compound exhibits good brain penetration and an adequate exposure time for clinical utility [3].
EnVivo changed its name to FORUM Pharmaceuticals Inc. in April 2014. ![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Encenicline is being assessed in several Phase 3 clinical trials as a potential treatment for imapired cognition in schizophrenia and in Alzheimer's disease. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
EVP-6124 is a selective, potent, brain penetrant oral compound that enhances synaptic transmission in the brain and acts as a co-agonist in combination with Acetylcholine (ACh) to enhance cognition [3] |